Role of gag in HIV resistance to protease inhibitors

Viruses

Volumn 2, Issue 7, 2010, Pages 1411-1426

  Clavel, François ^a,b,c   Mammano, Fabrizio ^d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT PASTEUR   (France)

^e CNRS   (France)

Author keywords

Gag; HIV 1; Mutations; Protease; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; PROTEIN PRECURSOR; PROTEINASE; PROTEINASE INHIBITOR; RO 033 4649; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ENZYME SUBSTRATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN CLEAVAGE; REVIEW; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952154269     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2071411     Document Type: Review

References (50)

1. Pettit, S.C.; Clemente, J.C.; Jeung, J.A.; Dunn, B.M.; Kaplan, A.H. Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J.Virol. 2005, 79, 10601-10607.
2. Pettit, S.C.; Lindquist, J.N.; Kaplan, A.H.; Swanstrom, R. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2005, 2, 66.
3. Pettit, S.C.; Moody, M.D.; Wehbie, R.S.; Kaplan, A.H.; Nantermet, P.V.; Klein, C.A.; Swanstrom, R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 1994, 68, 8017-8027.
4. Gross, I.; Hohenberg, H.; Wilk, T.; Wiegers, K.; Grattinger, M.; Muller, B.; Fuller, S.; Krausslich, H.G. A conformational switch controlling HIV-1 morphogenesis. EMBO J. 2000, 19, 103-113.
5. Krausslich, H.G.; Facke, M.; Heuser, A.M.; Konvalinka, J.; Zentgraf, H. The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J. Virol. 1995, 69, 3407-3419.
6. Shehu-Xhilaga, M.; Kraeusslich, H.G.; Pettit, S.; Swanstrom, R.; Lee, J.Y.; Marshall, J.A.; Crowe, S.M.; Mak, J. Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J. Virol. 2001, 75, 9156-9164.
7. Pettit, S.C.; Henderson, G.J.; Schiffer, C.A.; Swanstrom, R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 2002, 76, 10226-10233.
8. Bally, F.; Martinez, R.; Peters, S.; Sudre, P.; Telenti, A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retroviruses 2000, 16, 1209-1213.
9. Brumme, Z.L.; Chan, K.J.; Dong, W.W.; Wynhoven, B.; Mo, T.; Hogg, R.S.; Montaner, J.S.; O'Shaughnessy, M.V.; Harrigan, P.R. Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy. Antivir. Ther. 2003, 8, 91-96.
10. de Oliveira, T.; Engelbrecht, S.; Janse van Rensburg, E.; Gordon, M.; Bishop, K.; zur Megede, J.; Barnett, S.W.; Cassol, S. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J. Virol. 2003, 77, 9422-9430.
11. Gallego, O.; de Mendoza, C.; Corral, A.; Soriano, V. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J. Clin. Microbiol. 2003, 41, 1245-1247.
12. Verheyen, J.; Knops, E.; Kupfer, B.; Hamouda, O.; Somogyi, S.; Schuldenzucker, U.; Hoffmann, D.; Kaiser, R.; Pfister, H.; Kucherer, C. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naive patients. J. Infect. 2009, 58, 61-67.
13. Bandaranayake, R.M.; Prabu-Jeyabalan, M.; Kakizawa, J.; Sugiura, W.; Schiffer, C.A. Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6. J. Virol. 2008, 82, 6762-6766.
14. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C.A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002, 10, 369-381.
15. Condra, J.H.; Holder, D.J.; Schleif, W.A.; Blahy, O.M.; Danovich, R.M.; Gabryelski, L.J.; Graham, D.J.; Laird, D.; Quintero, J.C.; Rhodes, A.; Robbins, H.L.; Roth, E.; Shivaprakash, M.; Yang, T.; Chodakewitz, J.A.; Deutsch, P.J.; Leavitt, R.Y.; Massari, F.E.; Mellors, J.W.; Squires, K.E.; Steigbigel, R.T.; Teppler, H.; Emini, E.A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 1996, 70, 8270-8276.
16. Molla, A.; Korneyeva, M.; Gao, Q.; Vasavanonda, S.; Schipper, P.J.; Mo, H.M.; Markowitz, M.; Chernyavskiy, T.; Niu, P.; Lyons, N.; Hsu, A.; Granneman, G.R.; Ho, D.D.; Boucher, C.A.; Leonard, J.M.; Norbeck, D.W.; Kempf, D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 1996, 2, 760-766.
17. Prabu-Jeyabalan, M.; Nalivaika, E.A.; King, N.M.; Schiffer, C.A. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 2004, 78, 12446-12454.
18. Logsdon, B.C.; Vickrey, J.F.; Martin, P.; Proteasa, G.; Koepke, J.I.; Terlecky, S.R.; Wawrzak, Z.; Winters, M.A.; Merigan, T.C.; Kovari, L.C. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J. Virol. 2004, 78, 3123-3132.
19. Prabu-Jeyabalan, M.; King, N.M.; Nalivaika, E.A.; Heilek-Snyder, G.; Cammack, N.; Schiffer, C.A. Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 2006, 50, 1518-1521.
20. Prabu-Jeyabalan, M.; Nalivaika, E.A.; Romano, K.; Schiffer, C.A. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J. Virol. 2006, 80, 3607-3616.
21. Mammano, F.; Trouplin, V.; Zennou, V.; Clavel, F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 2000, 74, 8524-8531.
22. Martinez-Picado, J.; Savara, A.V.; Sutton, L.; D'Aquila, R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 1999, 73, 3744-3752.
23. Zennou, V.; Mammano, F.; Paulous, S.; Mathez, D.; Clavel, F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 1998, 72, 3300-3306.
24. Nijhuis, M.; Schuurman, R.; de Jong, D.; Erickson, J.; Gustchina, E.; Albert, J.; Schipper, P.; Gulnik, S.; Boucher, C.A. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13, 2349-2359.
25. Barbour, J.D.; Wrin, T.; Grant, R.M.; Martin, J.N.; Segal, M.R.; Petropoulos, C.J.; Deeks, S.G. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 2002, 76, 11104-11112.
26. Bleiber, G.; Munoz, M.; Ciuffi, A.; Meylan, P.; Telenti, A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 2001, 75, 3291-3300.
27. Carron de la Carriere, L.; Paulous, S.; Clavel, F.; Mammano, F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J. Virol. 1999, 73, 3455-3459.
28. Mammano, F.; Petit, C.; Clavel, F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 1998, 72, 7632-7637.
29. Doyon, L.; Croteau, G.; Thibeault, D.; Poulin, F.; Pilote, L.; Lamarre, D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 1996, 70, 3763-3769.
30. Zhang, Y.M.; Imamichi, H.; Imamichi, T.; Lane, H.C.; Falloon, J.; Vasudevachari, M.B.; Salzman, N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 1997, 71, 6662-6670.
31. Banke, S.; Lillemark, M.R.; Gerstoft, J.; Obel, N.; Jorgensen, L.B. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J. Virol. 2009, 83, 8916-8924.
32. Brann, T.W.; Dewar, R.L.; Jiang, M.K.; Shah, A.; Nagashima, K.; Metcalf, J.A.; Falloon, J.; Lane, H.C.; Imamichi, T. Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness. J. Virol. 2006, 80, 6136-6145.
33. Cote, H.C.; Brumme, Z.L.; Harrigan, P.R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 2001, 75, 589-594.
34. Maguire, M.F.; Guinea, R.; Griffin, P.; Macmanus, S.; Elston, R.C.; Wolfram, J.; Richards, N.; Hanlon, M.H.; Porter, D.J.; Wrin, T.; Parkin, N.; Tisdale, M.; Furfine, E.; Petropoulos, C.; Snowden, B.W.; Kleim, J.P. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 2002, 76, 7398-7406.
35. Malet, I.; Roquebert, B.; Dalban, C.; Wirden, M.; Amellal, B.; Agher, R.; Simon, A.; Katlama, C.; Costagliola, D.; Calvez, V.; Marcelin, A.G. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J. Infect. 2007, 54, 367-374.
36. Robinson, L.H.; Myers, R.E.; Snowden, B.W.; Tisdale, M.; Blair, E.D. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retroviruses 2000, 16, 1149-1156.
37. Verheyen, J.; Litau, E.; Sing, T.; Daumer, M.; Balduin, M.; Oette, M.; Fatkenheuer, G.; Rockstroh, J.K.; Schuldenzucker, U.; Hoffmann, D.; Pfister, H.; Kaiser, R. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antiv. Ther. 2006, 11, 879-887.
38. Launay, O.; Duval, X.; Dalban, C.; Descamps, D.; Peytavin, G.; Certain, A.; Mouajjah, S.; Ralaimazava, P.; Verdon, R.; Costagliola, D.; Clavel, F. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). Antivir. Ther. 2006, 11, 889-899.
39. Prado, J.G.; Wrin, T.; Beauchaine, J.; Ruiz, L.; Petropoulos, C.J.; Frost, S.D.W.; Clotet, B.; D'Aquila, R.T.; Martinez-Picado, J. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002, 16, 1009-1017.
40. Dam, E.; Quercia, R.; Glass, B.; Descamps, D.; Launay, O.; Duval, X.; Krausslich, H.G.; Hance, A.J.; Clavel, F. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Path. 2009, 5, e1000345.
41. Nijhuis, M.; van Maarseveen, N.M.; Lastere, S.; Schipper, P.; Coakley, E.; Glass, B.; Rovenska, M.; de Jong, D.; Chappey, C.; Goedegebuure, I.W.; Heilek-Snyder, G.; Dulude, D.; Cammack, N.; Brakier-Gingras, L.; Konvalinka, J.; Parkin, N.; Krausslich, H.G.; Brun-Vezinet, F.; Boucher, C.A. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 2007, 4, e36.
42. Coren, L.V.; Thomas, J.A.; Chertova, E.; Sowder, R.C.; Gagliardi, T.D.; Gorelick, R.J.; Ott, D.E. Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J. Virol. 2007, 81, 10047-10054.
43. Moore, M.L.; Bryan, W.M.; Fakhoury, S.A.; Magaard, V.W.; Huffman, W.F.; Dayton, B.D.; Meek, T.D.; Hyland, L.; Dreyer, G.B.; Metcalf, B.W. Peptide substrates and inhibitors of the HIV-1 protease. Biochem. Biophys. Res. Commun. 1989, 159, 420-425.
44. Doyon, L.; Payant, C.; Brakier-Gingras, L.; Lamarre, D. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 1998, 72, 6146-6150.
45. Girnary, R.; King, L.; Robinson, L.; Elston, R.; Brierley, I. Structure-function analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors. J. Gen. Virol. 2007, 88, 226-235.
46. Parry, C.M.; Kohli, A.; Boinett, C.J.; Towers, G.J.; McCormick, A.L.; Pillay, D. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J. Virol. 2009, 83, 9094-9101.
47. Gatanaga, H.; Suzuki, Y.; Tsang, H.; Yoshimura, K.; Kavlick, M.F.; Nagashima, K.; Gorelick, R.J.; Mardy, S.; Tang, C.; Summers, M.F.; Mitsuya, H. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 2002, 277, 5952-5961.
48. Myint, L.; Matsuda, M.; Matsuda, Z.; Yokomaku, Y.; Chiba, T.; Okano, A.; Yamada, K.; Sugiura, W. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48, 444-452.
49. Knops, E.; Daumer, M.; Awerkiew, S.; Kartashev, V.; Schulter, E.; Kutsev, S.; Brakier-Gingras, L.; Kaiser, R.; Pfister, H.; Verheyen, J. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J. Antimicrob. Chemother. 2010, 65, 1472-1476.
50. Lambert-Niclot, S.; Flandre, P.; Malet, I.; Canestri, A.; Soulie, C.; Tubiana, R.; Brunet, C.; Wirden, M.; Katlama, C.; Calvez, V.; Marcelin, A.G. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. J. Antimicrob. Chemother. 2008, 62, 905-908.